Do you want to work in an environment that promotes free-minded scientific creativity, and translate your findings to impact medical practice and improve healthcare?
Are you excited to gain a new understanding of the molecular physiology and pathology of humans?
Do you want to join an international group of highly collaborative and successful colleagues that help you achieve your training and research goals?
Are you a person who enjoys teamwork across disciplines and within a broader cultural and social context?
If yes, apply now for one of our 15 fully funded PhD positions. The next PhD Program at CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences, and LBI-RUD, the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases in Vienna, together with our partners the Medical University of Vienna and the Children’s Cancer Research Institute (CCRI) of the St. Anna Children’s Hospital, will start in September 2021.
supervision by a top scientist and the entire Faculty at CeMM/LBI-RUD
a dynamic and highly multidisciplinary international research environment
full access to state-of-the-art facilities
a generous scholarship, which covers all research costs, university fees, work-related travel expenses, salary and health insurance for 4 years
a PhD degree awarded by the Medical University of Vienna
an exceptionally motivated PhD candidate with a keen interest in interdisciplinary teamwork and science that nurtures the precise, personalized, predictive and preventive medicine of the future
excellent in writing and speaking English
a candidate with (or soon to obtain) a final degree in medicine, biology, chemistry, bioinformatics, computer science, engineering, physics, mathematics or a similar subject (minimum requirement is a four-year Bachelor’s degree)
The research area
The 2021 CeMM PhD Program will focus on the thematic areas of Infection, Immunity, Metabolism, Cancer, Rare Diseases, Network Medicine, and Design Chemistry. We are also increasingly interested in patient-derived organoids. These areas are built on the pillars of epigenetics and genome integrity, bioinformatics and systems biology, high-throughput genetics, genomics and proteomics, molecular and cell biology, high content automatic imaging, chemical biology, and organic chemical synthesis.
Our goal is to enable and empower students with the ability to successfully design, execute, manage and explain a research project in modern molecular medicine, through a strongly participatory and interactive program. The program is conceptualized in three ‘modes’: collect, connect and contribute. These will guide you through scientific excellence in data generation and validation to responsible and professional scientific citizenship.
The host and partner institutes
CeMM and LBI-RUD are partner institutes with identical principles of excellence, competitiveness, internationality, as well as mentoring and training, together with the Medical University of Vienna and the CCRI they operate in a unique mode of super-cooperation. Here biology is connected with medicine, experiments with computation, discovery with translation, and science with society and the arts.
The mission of CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences is to achieve maximum scientific innovation in molecular medicine to improve healthcare. At CeMM, an international and creative team of scientists and medical doctors pursues free-minded, basic life science research in a large and vibrant hospital environment of outstanding medical tradition and practice. CeMM’s research is based on post-genomic technologies and focuses on societally important diseases, such as immune disorders and infections, cancer and metabolic disorders. The goal of CeMM is to pioneer the science that nurtures the precise, personalized, predictive and preventive medicine of the future.
LBI-RUD, the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases focuses its research on rare diseases of the immune system, hematopoiesis, and the nervous system. This research will not only provide the basis for targeted therapies, but also provide unique and novel insights into human biology far beyond the specific disease. LBI-RUD is highly connected in global networks promoting cooperation and synergy between different disciplines and engaging rare disease patients.
CeMM and LBI-RUD enjoy a privileged location right at the heart of the Medical Campus Vienna, one of the largest in Europe, door-to-door with the Medical University of Vienna, the Vienna General Hospital (AKH) and the CCRI. The Medical University of Vienna is the largest medical research institution in Austria and the AKH is one of the largest hospitals in Europe treating several hundred thousand people a year. The CCRI work hard to develop new and improved treatment options for the 250-300 children and adolescents diagnosed with cancer each year in Austria.
The partner institutions, CeMM, LBI-RUD, CCRI and the Medical University of Vienna are located within walking distance of Vienna’s historical city centre. Vienna is repeatedly ranked as the world’s best city to live in and is a United Nations city with a large international, English- speaking community. The official language at CeMM is English, and more than 45 different nationalities are currently represented at the institutes.
For more information about the partner institutes and the PhD Program, visit the websites:
www.cemm.oeaw.ac.at, https://rud.lbg.ac.at/, https://science.ccri.at/ and https://www.meduniwien.ac.at/web/en/
CeMM PhD Program
Apply now online: https://www.phdprogram.cemm.oeaw.ac.at/?selection=cemm21
The next PhD Program of CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna will start in September 2021. We are offering 15 fully funded PhD positions at CeMM and LBI-RUD and are looking for exceptionally motivated candidates!
Medics, Biologists, Chemists, Bioinformaticians, Computer Scientists, Engineers, Physicists, Mathematicians, and candidates with a degree in a similar subject please apply now.
Deadline: 27 January 2021